ArticleClinical pharmacology and therapeutics2010
Refilling and switching of antiepileptic drugs and seizure-related events.
Article in Clinical pharmacology and therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Effects of generic exchange of solid oral dosage forms in neurological disorders: a systematic review.International journal of clinical pharmacy · 2020Pooled it
- Drug Brand Switching: A Regulatory Perspective.Drug safety · 2026Review
- Medications, epilepsy and climate change: Added layers of complexity.British journal of clinical pharmacology · 2025Review
- Commentary: Consensus Guidelines on the Appropriate Use of Brand-Name and Generic Anti-Seizure Medication for the Management of Epilepsy in the Gulf Region.Neurology and therapy · 2023Article
- Attitudes towards the switching of anti-epileptic medications in pharmacies: the patients' perspective.Postepy psychiatrii neurologii · 2023Article
- Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions.JAMA internal medicine · 2021Article
- Considerations over a Case of Suspected Therapeutic Failure in Pediatric Patients after Switching Valproate Manufacturers.Innovations in pharmacy · 2020Article
- A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications.Journal of general internal medicine · 2019Article
- Evaluation of Switching Patterns in FDA's Sentinel System: A New Tool to Assess Generic Drugs.Drug safety · 2018Article
- Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2018Article
- Active Surveillance of Follow-on Biologics: A Prescription for Uptake.Drug safety · 2017Article
- Safety of switching from brand-name to generic levetiracetam in patients with epilepsy.Drug design, development and therapy · 2017Article
- Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study.Neurology · 2016Article
- Potentially disruptive life events: what are the immediate impacts on chronic disease management? A case-crossover analysis.BMJ open · 2016Observational
- A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials.British journal of clinical pharmacology · 2016Article
- Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness.Drug safety · 2015Article
- Observational
- Article
- Generic drugs for hypertension: are they really equivalent?Current hypertension reports · 2013Review
- Rational use of generic psychotropic drugs.CNS drugs · 2013Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
We sought to estimate the risk of seizure-related events associated with refilling prescriptions for antiepileptic drugs (AEDs) and to estimate the effect of switching between brand-name and generic drugs or between two generic versions of the same drug. We conducted a case-crossover study using health-care databases from British Columbia, Canada, among AED users who had an emergency room visit or hospitalization for seizure (index seizure-related event), defined using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) codes 345.xx (epilepsy and recurrent seizures) and 780.3x (convulsions), between 1997 and 2005. AED prescription refilling itself was associated with 2.3-fold elevated odds of seizure-related events when the refill occurred within 21 days before the index event (odds ratio (OR) 2.31; 95% confidence interval (CI) 1.56-3.44). The OR was 2.75 (95% CI 0.88-8.64) for refills that involved switching, yielding a refill-adjusted OR for switching of 1.19 (95% CI 0.35-3.99). Refilling the same AED prescription was associated with an elevated risk of seizure-related events whether or not the refill involved switching from a brand-name to a generic product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.